Coya Therapeutics Reports that Subcutaneously Dosed COYA 302 Shows Direct Anti-Inflammatory Effects in the Brain in a Mouse Model of Parkinson’s Disease.
Dupixent, the pioneering biologic, has shown remarkable success in reducing symptoms and achieving disease remission in a pivotal study on bullous pemphigoid.
Nxera Pharma's collaborator Centessa reveals encouraging interim Phase 1 clinical results for their new OX2R agonist, ORX750, in healthy volunteers with acute sleep deprivation.
The U.S. FDA has approved TREMFYA® (guselkumab) for adults with moderate to severe ulcerative colitis, bolstering Johnson & Johnson's position in the inflammatory bowel disease market.
Cytokinetics, Incorporated (Nasdaq: CYTK) disclosed that data from the Phase 1 clinical trial of CK-4021586 (CK-586) were showcased during a poster presentation at the ACCP Annual Meeting.
CytomX Therapeutics reports initial patient treatment with CX-801, a dual-masked Interferon-Alpha 2b PROBODY®, in a Phase 1 trial for solid tumor patients.
Sep 14th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Boehringer's zongertinib demonstrates promising effectiveness and tolerability in patients with HER2-mutated lung cancer who have undergone prior treatment.